A series of prospective studies provide consistent data documenting that mild elevation of baseline levels of CRP among apparently healthy individuals is associated with higher long-term risk for future cardiovascular events. This predictive capacity of CRP is independent of traditional cardiovascular risk factors and offers a prognostic advantage over measurement of lipid alone. Inflammatory markers specifically hsCRP may help to identify those who would benefit most from these pharmacological intervention. hsCRP is the novel and evolving biomarker which provides a most useful predictive indicator for subsequent cardiovascular events.
This test should not be used for assessment of acute inflammation but should be ordered to evaluate CVD (Cardiovascular Disease) risk in apparently healthy individuals who have not had recent infection or other serious illness. For the assessment of acute inflammation the CRP ELISA ref 740001 from apDia can be used.